Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says

(February 29, 2016, 10:38 AM EST) -- LONDON — The investigational drug Tremelimumab does not improve overall survival rates of mesothelioma patients when used alone, AstraZeneca announced Feb. 29.

In its release, AstraZeneca said Tremelimumab remains a key component in combination treatments for various types of tumors.

Tremelimumab is currently being studied in combination with another AstraZeneca drug, Durvalumab, as a treatment for numerous tumors, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers, the company said.

Tremelimumab is a selective antibody drug...
To view the full article, register now.